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INTRODUCTION
Neurons, like all cells, must achieve a delicate balance 
between synthesis and degradation of proteins to maintain 
a healthy existence. The complex machinery that regulates 
protein homeostasis is an example of how cells maintain a 
necessary equilibrium to comply with spatial limitations and 
functional need. Continuous surveillance of the intracellular 
environment is accomplished by the combined action of the 
chaperone network (a conglomerate of proteins that aids 
in protein folding and assembly) and protein degradation 
pathways (microsystems that degrade proteins and recycle 
their constituent amino acids). These mechanisms ensure 
that misfolded proteins and damaged organelles can be rap-
idly identified and eliminated. Failure to perform this quality 
control leads to accumulation of damaged products that are 
toxic for cells and can precipitate loss of cellular functionality 
and even cell death (Morimoto & Cuervo, 2009).
Protein degradation pathways are essential for pre-
serving neuronal health, functionality, and homeostasis. 
Autophagy—a term that means “self-eating”—is one such 
protein degradation pathway that functions to degrade a 
diverse array of cellular components in vesicular organelles 
called lysosomes (Figure 1). Lysosomes contain a collection 
of more than 60 acid hydrolases capable of cleaving and 
digesting most biological material (Schroder, Wrocklage, 
Hasilik, & Saftig, 2010). After digestion, breakdown prod-
ucts are shipped back into the cytosolic compartment by 
transporters embedded in the lysosomal membrane. 
Autophagy is a complex process because it involves the 
sensing, sequestering, and targeting of cargo (i.e., damaged 
organelles and misfolded proteins). Different mechanisms of 
cargo delivery to lysosomes exist, including de novo forma-
tion of cargo-containing autophagosomal vesicles that fuse 
with lysosomes (in macroautophagy), receptor-mediated 
translocation of cytosolic proteins across the lysosomal 
membrane (in chaperone-mediated autophagy), and invagi-
nation and pinching off of portions of the lysosomal mem-
brane (in microautophagy) (Yang & Klionsky, 2010). More 
than 30 autophagy-related genes (ATGs) and their protein 
products have been identified to participate in these various 
steps of autophagy. These include molecules involved in 
signal transduction (e.g., PI3K, BECN1), autophagosome 
formation and elongation (e.g. ATG5, ATG12, ATG16), and 
lipid conjugation (e.g. LC3, ATG3) (Mizushima, Yoshimori, 
& Ohsumi, 2011). In addition to the genes that comprise 
the core autophagic machinery, there are other regulatory 
proteins that serve to modulate autophagy activity either 
through activation or inhibition. These include genes such 
as ULK2, which has been shown to be necessary for proper 
autophagy induction in mammals (Mizushima, 2010); BCL2, 
which inhibits Beclin1-dependent autophagy (Pattingre et 
al., 2005); and ADNP, which encodes a binding partner of 
LC3, a critical component of the autophagosome (Gozes 
& Ivashko-Pachima, 2015). Regardless of the mechanism 
or genes that are involved, a major role of autophagy is to 
identify and eliminate potentially toxic materials before they 
accumulate inside post-mitotic neurons and lead to dysfunc-
tion and death. Additionally, autophagy has been shown to 
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Autophagy, the process of degrading intracellular compo-
nents in lysosomes, plays an important role in the central 
nervous system by contributing to neuronal homeostasis. 
Autophagic failure has been linked to neurologic dysfunc-
tion and a variety of neurodegenerative diseases. Recent 
investigation has revealed a novel role for autophagy in 
the context of mental illness, namely in schizophrenia. 
This article summarizes the phenomenology, genetics, 
and structural/histopathological brain abnormalities asso-
ciated with schizophrenia. We review studies that demon-
strate for the first time a connection between autophagy 
malfunction and schizophrenia. Transcriptional profiling 
in schizophrenia patients uncovered a dysregulation of 
autophagy-related genes spatially confined to a specific 
area of the cortex, Brodmann Area 22, which has been 
previously implicated in the positive symptoms of schizo-
phrenia. We also discuss the role of autophagy activators 
in schizophrenia and whether they may be useful adju-
vants to the traditional antipsychotic medications cur-
rently used as the standard of care. In summary, the field 
has progressed beyond the basic concept that autophagy 
impairment predisposes to neurodegeneration, to a 
mechanistic understanding that loss of autophagy can 
disrupt neuronal cell biology and predispose to mood 
disorders, psychotic symptoms, and behavioral change.
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Figure 1 | Autophagy in Neuronal Cells. The process of autophagy refers to the intracellular degradation of proteins and organelles inside 
lysosomes. The broken-down material is subsequently recycled by release back into the cytoplasm. Autophagy helps to maintain neuronal 
homeostasis by degrading damaged proteins and dysfunctional organelles that could otherwise result in cellular toxicity and death.
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have several other important functions in neurons, such as 
recycling of basic metabolites for new synthesis and energy 
stores, facilitating the adaptive stress response, contributing 
to development, and regulating synaptic plasticity (Nixon, 
2013; Nikoletopoulou, Papandreou, & Tavernarakis, 2015).
Autophagic failure has been linked to neurologic dysfunc-
tion and a variety of neurodegenerative diseases (Nixon & 
Yang, 2012; Schneider & Cuervo, 2013). Studies have shown 
that blockage of the autophagy pathway in neurons leads 
to cell death and early-onset neurodegeneration in rodent 
models (Hara et al., 2006). Moreover, there is strong evi-
dence demonstrating that dysfunctional autophagy is asso-
ciated with disorders such as Alzheimer’s disease (J.-H. Lee 
et al., 2010), Parkinson’s disease (Orenstein et al., 2013), 
Huntington’s disease (Ravikumar et al., 2004), and tauopa-
thies (Wang, Martinez-Vicente, et al., 2009). 
In addition to its role in neurodegeneration, autophagy is 
now being investigated in the context of psychiatric illness. 
Studies from the past five years have illustrated a potentially 
important connection between autophagic dysfunction and 
schizophrenia, a mental illness that affects approximately 
one percent of the world’s population and causes debili-
tating social and occupational impairment. Diagnostic cri-
teria for schizophrenia include the presence of two or more 
positive symptoms—such as hallucinations and delusions—
or negative symptoms—such as blunted emotional respon-
siveness, poverty of speech, and amotivation (Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5), 2013). Positive symptoms represent an exaggera-
tion of normal processes that result in a distortion of reality, 
often manifested as auditory hallucinations and paranoid 
delusions. Disorganized speech and behavior are also hall-
marks of schizophrenia and encompass findings such as tan-
gential speech, derailment, neologisms, and incoherence. 
Negative symptoms, on the other hand, are conceptualized 
as an absence or diminution of normal processes, or deficit 
symptoms. Patients with negative symptoms may exhibit 
blunted or flattened affect, alogia, avolition, and anhedonia 
(Andreasen & Olsen, 1982). 
THE BASIS OF SCHIZOPHRENIA: GENETIC, 
ENVIRONMENTAL, PATHOLOGICAL AND MOLECULAR 
ASPECTS
From our current understanding of the illness, schizophrenia 
is likely the result of complex interactions between genetic 
and environmental factors that predispose to abnormalities 
in the central nervous system. Schizophrenia is believed to 
have a strong genetic component given that family, twin 
concordance, and adoption studies have all demonstrated 
a high degree of heritability. The concordance rate has been 
reported to be as high as 40 to 50% in monozygotic twins 
and 10 to 15% in dizygotic twins (Kringlen, 2000). Recent 
genome-wide association studies (GWAS) have identified 
22 risk loci and thousands of genetic changes (single-nucle-
otide polymorphisms, SNPs) that could contribute to one’s 
risk (Ripke et al., 2013). While the increased concordance 
among monozygotic twins suggests a strong genetic com-
ponent, the fact that the concordance rate doesn’t reach 
100% suggests that there are additional environmental fac-
tors that influence one’s risk for developing schizophrenia.
Although there seems to be a genetic component to the 
etiology of schizophrenia, it appears that there is no single 
gene solely responsible for causing the disease. However, 
emerging evidence suggests that environmental influences 
may have a significant contribution. These factors include 
perinatal complications, drug use, and traumatic brain 
injury. Various obstetrical difficulties such as hemorrhage, 
preterm labor, maternal-fetal blood group incompatibility, 
and fetal hypoxia may increase the risk of developing 
schizophrenia by up to two-fold (Clarke, Harley, & Cannon, 
2006). There is evidence that maternal infections (especially 
TORCH infections such as toxoplasmosis), as well as other 
pregnancy-related complications such as nutritional defi-
ciencies, allergies, and maternal stress may predispose to 
schizophrenia (Svrakic, Zorumski, Svrakic, Zwir, & Cloninger, 
2013). Epidemiological studies have revealed that certain 
illicit drugs, namely cannabis, increase one’s risk (van Os et 
al., 2002), as does suffering from an early traumatic brain 
injury, specifically if it leads to frontal and temporal lobe 
damage (Nicholl & LaFrance, 2009). 
In addition to understanding the biological and environ-
mental predisposing factors, there is clinical interest in deci-
phering structural and histopathological abnormalities of the 
brain that are associated with schizophrenia. Experts believe 
that different brain regions play distinct roles in positive and 
negative symptomatology, an idea that is supported by 
the observation that antipsychotic agents that antagonize 
dopamine receptors alleviate positive symptoms (J. Lee et 
al., 2015). For instance, blockage of dopamine (D2) recep-
tors in the auditory and auditory-visual association cortices 
(Brodmann Areas 22, 39, 42, 20, and 37) is one proposed 
mechanism for a reduction in hallucinatory behavior in schizo-
phrenia (Goldsmith, Shapiro, & Joyce, 1997). Nonetheless, 
global changes in the brain have been identified and linked 
to schizophrenia, such as the bilateral enlargement of ven-
tricles that reflects an underlying loss of tissue in the cen-
tral nervous system (Styner et al., 2005). Postmortem brain 
neuropathology in schizophrenia has revealed synaptic and 
dendritic deficits in the cerebral cortex and hippocampus 
(Benes, Kwok, Vincent, & Todtenkopf, 1998). These findings 
on pathology have been correlated with neuroimaging evi-
dence that shows reduced grey matter volume and a 40% 
reduction in volume in the CA2 region of the hippocampus 
(Glantz, Gilmore, Lieberman, & Jarskog, 2006). Furthermore, 
a particular area of the prefrontal cortex, Brodmann Area 10 
(BA10), has been reported to have functional connectivity 
impairment in patients with schizophrenia, which is believed 
to correlate with deficits in memory (Wang, Cui, et al., 2009).
While there have been numerous studies exploring the 
genetic, environmental, and pathological aspects of the 
illness, the molecular basis of schizophrenia is still poorly 
understood. To appreciate the molecular underpinnings 
of schizophrenia, investigators have started examining the 
changes in gene expression associated with schizophrenia 
and how these alterations in neuronal cell biology may 
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underlie positive and negative symptoms (Narayan et al., 
2008). Excitingly, global gene expression studies have iden-
tified changes in transcriptional regulation of genes related 
to myelination, synaptic transmission, metabolism, and, 
most recently, autophagy (Barnes et al., 2011). Therefore, 
it is reasonable to hypothesize that failure of autophagy in 
neurons may lead to cellular dysfunction and global changes 
in distinct brain regions that contribute to the development 
of symptoms of schizophrenia.
THE FIRST STUDIES LINKING AUTOPHAGY TO 
SCHIZOPHRENIA
Large-scale, high-throughput analyses were the first tests 
of choice to help uncover molecular changes that are asso-
ciated with schizophrenia. To determine whether schizo-
phrenia is accompanied by alterations in gene expression 
in certain regions of the brain, investigators compared 
gene expression profiles across multiple brain areas of 
postmortem patients who fell into either of two groups: 
those who were cognitively normal (no neuro- or psychopa-
thology), and those who had been diagnosed with schizo-
phrenia (Horesh, Katsel, Haroutunian, & Domany, 2011). 
Strikingly, this unbiased analysis revealed a gross impair-
ment in autophagy-related gene expression in brains from 
schizophrenia patients, particularly in Brodmann Area 22 
(BA22) of the superior temporal cortex, a region already 
hypothesized to be involved in the pathogenesis of schizo-
phrenia (Horesh et al., 2011; Rapoport et al., 1999). The 
molecular signatures that demonstrated the highest sig-
nificance (p=0.00039), differentiating affected brains from 
control specimens, were a cluster of genes involved in the 
regulation of autophagy. Microarray analysis of these brains 
showed that several genes that are key in neuronal autoph-
agic function exhibited decreased expression levels in the 
BA22 region. The list included genes like ULK2, ATG3, and 
PI3KR4, which are involved in different facets of macroau-
tophagy (regulation, signaling, autophagosome formation 
and lipid modification, respectively) (Kroemer, Mariño, 
& Levine, 2010). Thus, this study concluded that patients 
who had been diagnosed with schizophrenia during their 
lifetimes exhibited a decrease in mRNA expression of sev-
eral autophagy-related genes, suggesting for the first time 
a molecular link between schizophrenia and autophagic 
dysfunction.
A second group performed a similar transcriptional analysis 
of mRNA expression levels in postmortem samples from 
19 control patients and 23 schizophrenia patients. This 
study compared two different brain regions thought to be 
involved in the positive and negative symptoms of schizo-
phrenia (Barnes et al., 2011). Gene expression was analyzed 
in the BA22 region, which is hypothesized to play a role 
in the development of the positive symptoms of schizo-
phrenia. Similarly, genetic profiling was done on the anterior 
prefrontal cortex (BA10), which is thought to contribute to 
the negative symptoms of schizophrenia. Interestingly, the 
results demonstrated that autophagic dysregulation was 
a prominent feature only in the BA22 region, but not the 
BA10 region, thus reaffirming the concept that autophagy 
dysregulation occurs in the brain region associated with 
positive symptoms (Barnes et al., 2011). The authors pro-
posed that autophagy failure is more highly associated with 
positive symptom pathophysiology due to the spatial dys-
regulation of autophagy gene expression in specific brain 
regions of patients diagnosed with schizophrenia. 
After these transcriptional profiling studies established a 
connection between schizophrenia and autophagic gene 
dysregulation, the question became: Does autophagy 
failure contribute to the pathogenesis of schizophrenia and, 
if so, how?
AUTOPHAGY AND SCHIZOPHRENIA: UNDERSTANDING 
THE MECHANISM
A recently published landmark study by Merenlender-Wagner 
et al. proposed a mechanism for neuronal dysregulation 
in schizophrenia that is due to autophagy (Merenlender-
Wagner et al., 2015). This group showed that there is a 
statistically significant reduction in mRNA levels of a crucial 
autophagy-related protein, Beclin 1 (BECN1), in the hippo-
campus of schizophrenia patients. A BECN1-interacting pro-
tein, BCL2, was also found to have altered transcript levels in 
the postmortem hippocampal region of these same patients. 
Since BECN1 plays a critical role in autophagy induction, 
a decrease in its expression may result in impairment of 
autophagy in hippocampal neuronal cells, thus limiting their 
capacity to degrade damaged components inside the cel-
lular milieu (Merenlender-Wagner et al., 2015). 
In contrast to the decrease in BECN1 in schizophrenia 
patients, another autophagy-related protein called activity-
dependent neuroprotective protein (ADNP) exhibits 
increased levels in both the brain and circulating lympho-
cytes in schizophrenia. ADNP is a binding partner of LC3, 
a key component of the autophagic machinery. Merlender-
Wagner and colleagues postulated that disturbance of 
ADNP in schizophrenia has a negative effect on autophagic 
activity via LC3. Interestingly, ADNP levels are also altered 
outside of the brain and in peripheral blood, suggesting 
that this protein may serve as a biomarker for certain types 
of psychiatric illness (Merenlender-Wagner et al., 2015).
Administration of NAP, a peptide fragment of ADNP also 
known as davunetide, enhanced the ADNP-LC3 interaction 
and reversed the decrease in hippocampal BECN1 mRNA 
levels in a mouse model of schizophrenia (MAP6-deficiency) 
(Merenlender-Wagner et al., 2014). Normalization of 
BECN1 expression by NAP led to positive outcomes in 
the behavioral phenotype of MAP6-deficient mice. The 
changes observed in treated animals included decreased 
hyper-locomotion and cognitive deficits as measured by 
the object recognition test. The combination of NAP with 
clozapine, an FDA-approved antipsychotic used in refrac-
tory schizophrenia, resulted in complete normalization of 
behavioral outcomes (Merenlender-Wagner et al., 2014). 
These studies highlight a potential role for NAP-mediated 
autophagy rescue in mouse models of schizophrenia and 
suggest a new therapeutic strategy of supplying adjuvant 
treatment along with antipsychotic medication to bolster 
the efficacy of therapy.
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AUTOPHAGY AND ANTIPSYCHOTICS
Medications used to treat a variety of psychiatric illnesses may 
function in part through induction of autophagy. Previous 
studies demonstrated that the mood-stabilizing drug 
lithium, used to treat bipolar disorder, induces autophagy 
(Sarkar & Rubinsztein, 2008). This finding prompted others 
to evaluate whether antipsychotic agents have an effect on 
autophagy activity in the brain. Zhang and colleagues used 
a small molecule screen to show that three FDA-approved 
antipsychotic agents (fluspirilene, trifluoperazine, and pimo-
zide) are all inducers of autophagy (Zhang et al., 2007). This 
suggests that downregulation of autophagic genes in certain 
brain regions of schizophrenia patients might be reversed, 
at least in part, by antipsychotic drugs that drive autophagy 
activity and enhance the expression of autophagy-related 
proteins in the BA22 region.
However, the relationship between autophagy and antipsy-
chotic medication is not entirely clear. Conflicting studies in 
rat primary neurons have demonstrated that certain typical 
and atypical antipsychotics (haloperidol and clozapine) 
actually block autophagy activity by inhibiting the forma-
tion of autophagolysosomes, a key intermediate compart-
ment necessary for lysosomal degradation of intracellular 
cargo (Park et al., 2012). This study also showed that these 
medications decrease neuronal viability through autophagic 
inhibition. Therefore, the effect of antipsychotic medication 
on autophagy may depend on the type of drug, the region 
of the brain affected, and other unknown confounding 
variables. In any case, it will be important to test whether 
certain antipsychotic medications act via autophagy, how 
this occurs, and whether adding therapeutic agents that 
modulate autophagic activity can enhance the efficacy of 
the medications currently used as the standard of care.
CONCLUSION
The cellular process of autophagy may be an important 
contributor to the pathophysiology of psychiatric disease, 
namely schizophrenia. While previous studies have estab-
lished that the failure of autophagy predisposes to neuro-
degeneration and dementia, recent findings have linked 
autophagy to neuropsychiatric disease and have helped 
to elucidate potential underlying molecular mechanisms 
in schizophrenia. The traditional view was that autophagic 
compromise leads to protein misfolding and subsequent 
aggregation, which in turn drives neuronal cell death and 
early dementia. Now, we are beginning to understand that 
loss of autophagy may also disrupt neuronal cell biology in 
a way that predisposes to mood disorders, psychotic symp-
toms, and behavioral change (Polajnar & Zerovnik, 2014). 
Going forward, additional research is needed to establish 
whether functional changes in autophagic activity occurs 
in schizophrenia patients. Until now, the studies linking 
autophagy to psychiatric disease have mainly focused on 
genetic profiling and steady-state levels of the genes and 
proteins involved in autophagy. Future areas of research 
will need to explore the mechanisms by which autophagy 
is actually impaired and whether this loss of function con-
tributes to positive or negative symptoms, or to both. 
Furthermore, GWAS studies can be performed to evaluate 
whether SNPs in autophagy-related genes may predispose 
to the development of schizophrenia, thus providing a novel 
explanation for inherited schizophrenia. Importantly, we still 
cannot distinguish whether autophagy failure predisposes 
to schizophrenia, or whether other molecular changes char-
acteristic of schizophrenia result in compromised autophagy. 
Teasing out whether autophagy impairment is a cause or a 
consequence of schizophrenia necessitates further studies 
using mammalian models of this disease.
In addition to the behavioral symptoms that are currently 
used to fulfill the diagnostic criteria of schizophrenia, future 
studies of autophagy and psychiatric illness may aid in the 
development of biomarkers that correlate with disease 
progression, severity, and responsiveness to treatment. 
Perhaps the contribution of autophagy to schizophrenia 
pathophysiology only occurs in a subset of patients; there-
fore biomarkers would be useful to identify which patients 
have an autophagic defect. If future studies continue to 
demonstrate a causative effect of autophagic malfunction 
on schizophrenia, small-molecule autophagy activators that 
cross the blood-brain barrier may serve as a useful adjunc-
tive therapeutic tool. Further investigation may support the 
implementation of autophagy activators in conjunction with 
other FDA-approved antipsychotic medications to target 
schizophrenia symptoms more effectively. 
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